Toni Pihlaja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Toni Pihlaja has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Matti Pokela
Department of Vascular Surgery, University of Oulu and Oulu University Hospital, Oulu, Finland
6 shared publicationsPasi Ohtonen
Research Service Unit, Oulu University Hospital, Oulu, Finland
6 shared publications- Harri Hakovirta
Department of Vascular Surgery, Turku University Hospital, Turku, Finland; University of Turku, Turku, Finland
3 shared publications Maarit Venermo
Department of Vascular Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
3 shared publications- Matti Pokela
Department of Vascular Surgery, University of Oulu and Oulu University Hospital, Oulu, Finland; Medical Research Center Oulu, University of Oulu, Oulu, Finland
3 shared publications Pekka Romsi
Department of Vascular Surgery, Oulu University Hospital, Oulu, Finland
3 shared publications
Latest Publications
- Open Access
- 22 January 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (6) , 1071-1079
Early Outcomes of a Randomised Controlled Trial Comparing Concomitant with Staged Tributary Treatment as an Adjunct to Endovenous Laser Ablation of the Saphenous Trunk: The FinnTrunk Study
- 22 January 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (6) , 1071-1079
Open AccessEarly Outcomes of a Randomised Controlled Trial Comparing Concomitant with Staged Tributary Treatment as an Adjunct to Endovenous Laser Ablation of the Saphenous Trunk: The FinnTrunk Study
- 17 April 2025
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 40 (9) , 713-718
Trial protocol for evaluating sub-ulcer foam sclerotherapy as an adjunct to conventional endovenous treatment in patients with venous leg ulcers: The FINNULCER multicenter randomized controlled trial
Background: Venous leg ulcers (VLUs) affect approximately 1% of the adult population and incur significant morbidity and healthcare costs. Endovenous interventions, such as endovenous laser ablation (EVLA) and ultrasound-guided foam sclerotherapy (UGFS), have shown benefits in treating venous insufficiency in patients with VLUs. However, the effect of specifically targeting the sub-ulcer venous plexus with foam sclerotherapy remains poorly understood. Objective: The FINNULCER trial is investigating the addition of sub-ulcer foam sclerotherapy to conventional endovenous treatment (EVLA + UGFS) for managing superficial venous insufficiency in patients with VLUs. The primary aim is to evaluate the effect of sub-ulcer foam sclerotherapy in promoting ulcer healing. Methods: Patients with VLUs are being screened at four vascular surgery units in Finland. Eligible participants who provide informed consent are randomized into the study group to receive sub-ulcer foam sclerotherapy + EVLA + UGFS or into the control group to receive EVLA + UGFS. The primary outcome is the time to ulcer healing during 1 year of follow-up from randomization. Secondary outcomes include quality of life assessments and procedure-related outcomes. Trial registration: ClinicalTrials.gov (NCT04737941).
- 17 April 2025
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 40 (9) , 713-718
Trial protocol for evaluating sub-ulcer foam sclerotherapy as an adjunct to conventional endovenous treatment in patients with venous leg ulcers: The FINNULCER multicenter randomized controlled trial
Background: Venous leg ulcers (VLUs) affect approximately 1% of the adult population and incur significant morbidity and healthcare costs. Endovenous interventions, such as endovenous laser ablation (EVLA) and ultrasound-guided foam sclerotherapy (UGFS), have shown benefits in treating venous insufficiency in patients with VLUs. However, the effect of specifically targeting the sub-ulcer venous plexus with foam sclerotherapy remains poorly understood. Objective: The FINNULCER trial is investigating the addition of sub-ulcer foam sclerotherapy to conventional endovenous treatment (EVLA + UGFS) for managing superficial venous insufficiency in patients with VLUs. The primary aim is to evaluate the effect of sub-ulcer foam sclerotherapy in promoting ulcer healing. Methods: Patients with VLUs are being screened at four vascular surgery units in Finland. Eligible participants who provide informed consent are randomized into the study group to receive sub-ulcer foam sclerotherapy + EVLA + UGFS or into the control group to receive EVLA + UGFS. The primary outcome is the time to ulcer healing during 1 year of follow-up from randomization. Secondary outcomes include quality of life assessments and procedure-related outcomes. Trial registration: ClinicalTrials.gov (NCT04737941).
- 27 November 2024
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 40 (5) , 324-329
Sub-ulcer foam sclerotherapy in patients with venous ulceration: A randomized controlled trial
Purpose: This trial analyzed the effect of sub-ulcer foam sclerotherapy in patients with venous leg ulcer (VLU). Design: Randomized controlled trial. Methods: This trial recruited patients with VLUs to receive either sub-ulcer foam sclerotherapy and compression therapy (study group) or compression therapy only (control group). The primary outcome of this study was the change in the venous ulcer area at 4 weeks. The feasibility, safety, and complications of the sub-ulcer foam sclerotherapy were recorded. Results: Of 23 patients included, 12 were randomized to study group and 11 to control group. Preoperatively, the average ulcer areas were 5.8 cm 2 in both groups. At 4 weeks, the average reductions in ulcer areas were 4.0 cm 2 (SD 3.1) in the study group (95% CI 2.0 to 5.9, p = .001) and 2.0 cm 2 (SD 3.1) in the control group (95% CI: −0.1 to 4.1, p = .051). No differences in complications were recorded. Conclusions: At 1-month sub-ulcer foam sclerotherapy and compression therapy reduced the ulcer area statistically significantly, whereas compression therapy alone did not. Sub-ulcer foam sclerotherapy could be a good addition to superficial venous insufficiency treatment in patients with VLU. ClinicalTrials.gov identifier NCT03795064.
- 27 November 2024
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 40 (5) , 324-329
Sub-ulcer foam sclerotherapy in patients with venous ulceration: A randomized controlled trial
Purpose: This trial analyzed the effect of sub-ulcer foam sclerotherapy in patients with venous leg ulcer (VLU). Design: Randomized controlled trial. Methods: This trial recruited patients with VLUs to receive either sub-ulcer foam sclerotherapy and compression therapy (study group) or compression therapy only (control group). The primary outcome of this study was the change in the venous ulcer area at 4 weeks. The feasibility, safety, and complications of the sub-ulcer foam sclerotherapy were recorded. Results: Of 23 patients included, 12 were randomized to study group and 11 to control group. Preoperatively, the average ulcer areas were 5.8 cm 2 in both groups. At 4 weeks, the average reductions in ulcer areas were 4.0 cm 2 (SD 3.1) in the study group (95% CI 2.0 to 5.9, p = .001) and 2.0 cm 2 (SD 3.1) in the control group (95% CI: −0.1 to 4.1, p = .051). No differences in complications were recorded. Conclusions: At 1-month sub-ulcer foam sclerotherapy and compression therapy reduced the ulcer area statistically significantly, whereas compression therapy alone did not. Sub-ulcer foam sclerotherapy could be a good addition to superficial venous insufficiency treatment in patients with VLU. ClinicalTrials.gov identifier NCT03795064.
- 4 April 2024
- Published by SAGE Publications in The International Journal of Lower Extremity Wounds
- Vol. 25 (2) , 509-514
Sub-ulcer Foam Sclerotherapy in Patients with Venous Leg Ulcer, Analysis and Technical Aspects of 134 Consecutive Patients
Objective: For this retrospective study, we analyzed the sub-ulcer foam sclerotherapy technique in patients with venous leg ulcer (VLU). Methods: This study included 134 patients treated with sub-ulcer foam sclerotherapy at the Oulu University Hospital vascular outpatient clinic from January 2012 to December 2021. All included patients received sub-ulcer foam sclerotherapy as part of the treatment strategy for superficial venous insufficiency. Compression therapy and local wound care were organized for VLU treatment. A follow-up visit was scheduled for one month after the sub-ulcer foam sclerotherapy. Change in ulcer size, local (skin necrosis, infection) or systemic (deep vein thrombosis, pulmonary embolism) complications, and time to ulcer healing were monitored. The occurrence of major limb-related complications (amputation, surgical revision) was monitored for one year postoperatively. Results: One month after sub-ulcer treatment, ulcers were smaller or completely healed in 108 (81%) patients. Ulcer healing was completed in 123 (92%) patients at one year and 131 (98%) patients at two years. Complications were recorded in four (3%) patients, three (2%) who were diagnosed with erysipelas requiring antibiotic treatment and one (1%) patient diagnosed with local dermatitis. During the one-year follow-up, no major limb-related complications (surgical revisions or amputations) arose. Conclusions: Sub-ulcer foam sclerotherapy may be a feasible addition to superficial vein reflux elimination in patients with VLU and a low risk for complications.
- 4 April 2024
- Published by SAGE Publications in The International Journal of Lower Extremity Wounds
- Vol. 25 (2) , 509-514
Sub-ulcer Foam Sclerotherapy in Patients with Venous Leg Ulcer, Analysis and Technical Aspects of 134 Consecutive Patients
Objective: For this retrospective study, we analyzed the sub-ulcer foam sclerotherapy technique in patients with venous leg ulcer (VLU). Methods: This study included 134 patients treated with sub-ulcer foam sclerotherapy at the Oulu University Hospital vascular outpatient clinic from January 2012 to December 2021. All included patients received sub-ulcer foam sclerotherapy as part of the treatment strategy for superficial venous insufficiency. Compression therapy and local wound care were organized for VLU treatment. A follow-up visit was scheduled for one month after the sub-ulcer foam sclerotherapy. Change in ulcer size, local (skin necrosis, infection) or systemic (deep vein thrombosis, pulmonary embolism) complications, and time to ulcer healing were monitored. The occurrence of major limb-related complications (amputation, surgical revision) was monitored for one year postoperatively. Results: One month after sub-ulcer treatment, ulcers were smaller or completely healed in 108 (81%) patients. Ulcer healing was completed in 123 (92%) patients at one year and 131 (98%) patients at two years. Complications were recorded in four (3%) patients, three (2%) who were diagnosed with erysipelas requiring antibiotic treatment and one (1%) patient diagnosed with local dermatitis. During the one-year follow-up, no major limb-related complications (surgical revisions or amputations) arose. Conclusions: Sub-ulcer foam sclerotherapy may be a feasible addition to superficial vein reflux elimination in patients with VLU and a low risk for complications.
- 9 August 2022
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 10 (6) , 1238-1244
Factors associated with delayed venous ulcer healing after endovenous intervention for superficial venous insufficiency
- 9 August 2022
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 10 (6) , 1238-1244
Factors associated with delayed venous ulcer healing after endovenous intervention for superficial venous insufficiency
- 1 March 2022
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 37 (4) , 303-311
Recovery and patient satisfaction following radiofrequency ablation and concomitant foam sclerotherapy of varicose veins with and without compression: A randomized controlled non-inferiority trial
Background: The benefits of postoperative compression are not well established following radiofrequency ablation of the truncal vein and concomitant foam sclerotherapy. Methods: A total of 104 patients were randomized: Postoperatively, 54 patients received no compression and 50 patients received class II thigh-high compression. The primary outcome for this study was the difference between means on postoperative pain scores over the first 10 days follow-up measured on a visual analog scale (VAS) from 0 to 100 mm (prespecified delta 10 mm). Results: The difference between means in no compression and compression group on postoperative pain scores over the 10 days follow-up was 2.1 mm (95% confidence interval −5.1–9.3 mm; p = 0.28) indicating non-inferiority. Patients in the no compression group were more satisfied with the visual appearance of the treated leg at 1 month ( p = 0.003). Conclusion: Over the first 10 postoperative days, no compression was non-inferior to compression on pain scores.
- 1 March 2022
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 37 (4) , 303-311
Recovery and patient satisfaction following radiofrequency ablation and concomitant foam sclerotherapy of varicose veins with and without compression: A randomized controlled non-inferiority trial
Background: The benefits of postoperative compression are not well established following radiofrequency ablation of the truncal vein and concomitant foam sclerotherapy. Methods: A total of 104 patients were randomized: Postoperatively, 54 patients received no compression and 50 patients received class II thigh-high compression. The primary outcome for this study was the difference between means on postoperative pain scores over the first 10 days follow-up measured on a visual analog scale (VAS) from 0 to 100 mm (prespecified delta 10 mm). Results: The difference between means in no compression and compression group on postoperative pain scores over the 10 days follow-up was 2.1 mm (95% confidence interval −5.1–9.3 mm; p = 0.28) indicating non-inferiority. Patients in the no compression group were more satisfied with the visual appearance of the treated leg at 1 month ( p = 0.003). Conclusion: Over the first 10 postoperative days, no compression was non-inferior to compression on pain scores.
- 1 July 2021
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 9 (4) , 954-960
Ten years of experience with first-visit foam sclerotherapy to initiate venous ulcer healing
- 1 July 2021
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 9 (4) , 954-960
Ten years of experience with first-visit foam sclerotherapy to initiate venous ulcer healing